San Francisco Bay Area biotech stories.
Thursday, July 14, 2011
Bristol-Myers Squibb returns another cancer drug to Exelixis
Bristol-Myers Squibb is returning rights to an experimental cancer drug to Exelixis Inc. — the second time it has sent a drug back to the South San Francisco biotech company in little more than a year.
Share to Twitter
Share to Facebook
Share to Pinterest
Post a Comment
Post Comments (Atom)